RIGL logo

RIGEL PHARMACEUTICALS INC

RIGLNASDAQ
πŸ† #2485 by market capEarnings Mar 1 Β· PostUS Equity
$40.05β€”
Last available close Β· quote unavailable
πŸ””
Track RIGL
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ–Ό 9.9%
14dβ–² 1.1%
30dβ–Ό 16.9%
ytdβ–Ό 6.4%
1yβ–Ό 13.3%
🏦Market Cap
$755M
Small Cap
πŸ“ˆRevenue Growth (YoY)
64.2%
High Growth
πŸ“ŠGross Margin
89.6%
High
πŸ’΅FCF Margin
31.2%
Strong
βš–οΈP/S Ratio
2.6x
Cheap
Otter Score
84
Strong

Trading Snapshot

Day Range
β€”
52-Week Range
$24.95 – $52.61
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
18.8M
Next Earnings
2027-03-01

Fundamentals Snapshot

Annual Revenue
$294M
Last Q Revenue
$81M
P/E Ratio
2.4
P/S Ratio
2.6x
EPS (TTM)
$16.42
Dividend Yield
0.00%
Dilution (1yr)
+4.7%
RIGL logo

RIGEL PHARMACEUTICALS INC

RIGL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$294Mβ–² +64.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
93.3%β–² +4.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$125Mβ–² +418.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$76Mβ–² +143.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
18.8Mβ–² +4.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$13Mβ–Ό βˆ’$10M YoY
StockOtter Β· stockotter.space

About RIGEL PHARMACEUTICALS INC

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
84/100

Analyst Ratings

β“˜
Consensus
Buy
11 analysts
Strong Buy4
Buy4
Hold3
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

News unavailable.